This company has been acquired
The company may no longer be operating, as it has been acquired. Find out why through their latest events.
Sage Therapeutics（SAGE）株式概要
セージ・セラピューティクス社はバイオ医薬品会社で、脳の健康に役立つ医薬品を開発・販売している。 詳細
SAGE Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Sage Therapeutics, Inc. 競合他社
価格と性能
| 過去の株価 | |
|---|---|
| 現在の株価 | US$8.68 |
| 52週高値 | US$9.67 |
| 52週安値 | US$4.62 |
| ベータ | 0.30 |
| 1ヶ月の変化 | -4.41% |
| 3ヶ月変化 | 18.90% |
| 1年変化 | -9.58% |
| 3年間の変化 | -79.31% |
| 5年間の変化 | -82.88% |
| IPOからの変化 | -71.07% |
最新ニュース
Recent updates
新しいナラティブ • Mar 29
Expanding ZURZUVAE Demand Will Improve Postpartum And Neuropsych Care
Establishing ZURZUVAE as the PPD care standard should drive top-line growth through increased demand and brand visibility.Seeking Alpha • Jan 22
Sage Therapeutics: Looks Like A 'Strong Buy' With Zurzuvae's Potential And Biogen's Bid
Summary Sage Therapeutics has a unique approach to targeting GABA, which allows it to target CNS disorders. Its main asset is Zurzuvae, which is co-marketed with Biogen for PPD. BIIB recently made a bid for SAGE at $7.22 per share, which seems exceedingly cheap, considering SAGE has a lot of cash, and Zurzuvae is just ramping up its sales. SAGE is now contesting the takeover, which could lead to higher follow-up bids. This, I believe, adds upside optionality to the stock. Zurzuvae is also a relatively unique IP for PPD, as it has a simple 14-day regime that provides quick relief for depressive symptoms. This is why I think SAGE stock is a good buy at these levels. It seems undervalued as a standalone company or a takeover target with BIIB. Read the full article on Seeking AlphaSeeking Alpha • Jan 15
Sage Therapeutics: Biogen's Unsolicited Bid Is Best Step Forward For Shareholders
Summary The company remains a "hold" due to Biogen's unsolicited offer to acquire shares at a 30% premium, despite pipeline setbacks. The failure of the phase 2 DIMENSION study for dalzanemdor in treating cognitive impairment in Huntington's Disease highlights Sage's shrinking pipeline. Sage's financials indicate a need for additional funding in 2025, risking dilution and further financial instability. The future of SAGE-324 and SAGE-319 remains uncertain in treating patients with neurodevelopmental disorders, adding risk to the company's long-term prospects. Read the full article on Seeking AlphaSeeking Alpha • Nov 19
CNS Drug Development: Same As It Ever Was
Summary Sage Therapeutics has been working in the area of steroid-derived compounds that affect CNS receptor signaling. A pivotal trial failed to show benefit, and they had several other clinical failures as well. They have a clinical trial readout in Huntington's disease later this fall, and man, that's a tough place to make your stand. Read the full article on Seeking AlphaSeeking Alpha • Oct 07
Sage Therapeutics: With Dalzanemdor As The Last Lifeline, Not Much Hope Left
Summary Sage Therapeutics is a "sell" due to the failure of SAGE-324 in essential tremors and dalzanemdor's poor performance in Parkinson's Disease. Dalzanemdor's upcoming phase 2 studies for Huntington's and Alzheimer's diseases are unlikely to succeed, given prior trial results and similar primary endpoints. Financially, Sage has enough cash to operate until 2026, but without successful trials, raising additional funds will be challenging. Despite FDA approval of Zurzuvae for postpartum depression, it won't drive long-term growth; dalzanemdor's success is crucial for shareholder value creation. Read the full article on Seeking Alpha分析記事 • Aug 30
Why Investors Shouldn't Be Surprised By Sage Therapeutics, Inc.'s (NASDAQ:SAGE) 25% Share Price Plunge
Sage Therapeutics, Inc. ( NASDAQ:SAGE ) shareholders that were waiting for something to happen have been dealt a blow...Seeking Alpha • Jul 25
Sage Therapeutics: Tremors Of Trouble, But PPD Progress (Rating Downgrade)
Summary Sage Therapeutics, Inc.'s SAGE-324 failed its Phase 2b trial for essential tremor and development is discontinued. Dalzanemdor's past data in Parkinson's casts doubt on its prospects in other cognitive disorders. Zurzuvae's Q1 revenue exceeded expectations, but the market potential remains constrained by its narrow indication. Analysts are expecting $8.90 million in revenue for Q2. While Sage may exceed this, it isn't likely to move the stock much. Given clinical setbacks and limited revenue growth, I recommend downgrading Sage Therapeutics to “sell.”. Read the full article on Seeking Alpha分析記事 • Jul 13
Revenues Working Against Sage Therapeutics, Inc.'s (NASDAQ:SAGE) Share Price
You may think that with a price-to-sales (or "P/S") ratio of 7.8x Sage Therapeutics, Inc. ( NASDAQ:SAGE ) is a stock...Seeking Alpha • May 30
Sage Therapeutics Stock: Remains A Hold On Upcoming Essential Tremor Treatment Data
Summary Sage Therapeutics, Inc. results from phase 2b KINETIC 2 Study, using SAGE-324 for the treatment of patients with essential tremor, expected mid-2024. Top-line data from the phase 3 SURVEYOR study, using SAGE-718 for cognitive impairment in HD patients, expected in mid-2024. Top-line data from the phase 2 DIMENSION study, using SAGE-718 for cognitive impairment in HD patients, expected late-2024. Top-line data from the phase 2 LIGHTWAVE Study, using SAGE-718 for mild cognitive impairment or mild dementia due to Alzheimer's Disease, expected late-2024. Read the full article on Seeking Alpha分析記事 • May 21
Is Sage Therapeutics (NASDAQ:SAGE) In A Good Position To Invest In Growth?
We can readily understand why investors are attracted to unprofitable companies. For example, although...分析記事 • Feb 22
Analysts Have Just Cut Their Sage Therapeutics, Inc. (NASDAQ:SAGE) Revenue Estimates By 50%
The analysts covering Sage Therapeutics, Inc. ( NASDAQ:SAGE ) delivered a dose of negativity to shareholders today, by...分析記事 • Feb 15
Calculating The Fair Value Of Sage Therapeutics, Inc. (NASDAQ:SAGE)
Key Insights Sage Therapeutics' estimated fair value is US$29.43 based on 2 Stage Free Cash Flow to Equity Sage...Seeking Alpha • Jan 22
Sizing Up Sage Therapeutics
Summary Today, we take a deeper look at Sage Therapeutics, Inc., a biopharmaceutical company focused on developing brain health medicines. The stock has fallen sharply since June on a more limited FDA approval for the company's primary drug candidate. The drug has just been launched and management has taken actions to substantially lower annual operating costs. What's ahead for Sage Therapeutics in 2024? An analysis follows in the paragraphs below. Read the full article on Seeking Alpha分析記事 • Aug 09
Things Look Grim For Sage Therapeutics, Inc. (NASDAQ:SAGE) After Today's Downgrade
Today is shaping up negative for Sage Therapeutics, Inc. ( NASDAQ:SAGE ) shareholders, with the analysts delivering a...分析記事 • Feb 22
Here's Why We're Not Too Worried About Sage Therapeutics' (NASDAQ:SAGE) Cash Burn Situation
Just because a business does not make any money, does not mean that the stock will go down. For example, although...分析記事 • Nov 12
An Intrinsic Calculation For Sage Therapeutics, Inc. (NASDAQ:SAGE) Suggests It's 45% Undervalued
Today we will run through one way of estimating the intrinsic value of Sage Therapeutics, Inc. ( NASDAQ:SAGE ) by...分析記事 • Oct 14
Here's Why We're Not Too Worried About Sage Therapeutics' (NASDAQ:SAGE) Cash Burn Situation
Just because a business does not make any money, does not mean that the stock will go down. For example, although...Seeking Alpha • Aug 02
Sage Therapeutics GAAP EPS of -$2.13 beats by $0.02, revenue of $1.5M misses by $0.27M
Sage Therapeutics press release (NASDAQ:SAGE): Q2 GAAP EPS of -$2.13 beats by $0.02. Revenue of $1.5M (-8.5% Y/Y) misses by $0.27M. Cash Position: Cash, cash equivalents and marketable securities as of June 30, 2022 were $1.5 billion compared to $1.6 billion at March 31, 2022 Rolling NDA submission for zuranolone in MDD and PPD remains on track, with completion expected in the second half of 2022 Announced positive topline data from the Phase 3 SKYLARK Study evaluating 50 mg zuranolone for PPD Enrolling multiple Phase 2 studies across neuropsychiatry and neurology franchises, additional trials expected to initiate throughout 2022 Cash and cash equivalents, anticipated funding from ongoing collaborations, and potential revenue, expected to support operations into 2025分析記事 • Jun 15
We're Hopeful That Sage Therapeutics (NASDAQ:SAGE) Will Use Its Cash Wisely
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Seeking Alpha • Mar 24
Sage Therapeutics: Well-Funded But Uninspiring Data
Sage is well funded by Biogen. However, lead candidate SAGE-217 has not come up with strong MDD data. I continue to sit on the fence.株主還元
| SAGE | US Biotechs | US 市場 | |
|---|---|---|---|
| 7D | -1.4% | -1.6% | -0.8% |
| 1Y | -9.6% | 34.4% | 27.1% |
業界別リターン: SAGE過去 1 年間で34.4 % の収益を上げたUS Biotechs業界を上回りました。
リターン対市場: SAGEは、過去 1 年間で27.1 % のリターンを上げたUS市場を下回りました。
価格変動
| SAGE volatility | |
|---|---|
| SAGE Average Weekly Movement | 11.0% |
| Biotechs Industry Average Movement | 11.0% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 3.2% |
安定した株価: SAGEの株価は、 US市場と比較して過去 3 か月間で変動しています。
時間の経過による変動: SAGEの weekly volatility ( 11% ) は過去 1 年間安定していますが、依然としてUSの株式の 75% よりも高くなっています。
会社概要
| 設立 | 従業員 | CEO（最高経営責任者 | ウェブサイト |
|---|---|---|---|
| 2010 | 353 | Barry Greene | www.sagerx.com |
バイオ医薬品企業であるセージ・セラピューティクス社は、脳の健康に役立つ医薬品の開発・商品化を行っている。同社は、シナプスおよびシナプス外GABA受容体を標的とした神経活性ステロイドGABA受容体陽性アロステリックモジュレーターであるZURZUVAEを、成人の産後うつ病の治療薬として提供している。また、新規GABA受容体陽性アロステリックモジュレーターであるSAGE-324は、発達障害やてんかん性脳症の発作を含む慢性経口投与用、SAGE-319は、神経発達障害に伴う行動症状を治療するシナプス領域外優先GABA受容体陽性アロステリックモジュレーターPAM。さらに、神経発達障害の治療に焦点を当てたNMDA受容体陰性アロステリックモジュレーターだけでなく、脳内のGABAおよびNMDA受容体システムのアロステリックモジュレーションに関する研究を含む、急性および慢性の脳の健康障害の治療のためのSAGE-817およびSAGE-039を含む様々な製品候補を開発している。以前はSterogen Biopharma, Inc.として知られていたが、2011年9月にSage Therapeutics, Inc.に社名を変更した。セージ・セラピューティクス社は2010年に法人化され、マサチューセッツ州ケンブリッジに本社を置いている。
Sage Therapeutics, Inc. 基礎のまとめ
| SAGE 基礎統計学 | |
|---|---|
| 時価総額 | US$543.56m |
| 収益（TTM） | -US$301.19m |
| 売上高(TTM) | US$70.41m |
7.7x
P/Sレシオ-1.8x
PER（株価収益率SAGE は割高か？
公正価値と評価分析を参照収益と収入
| SAGE 損益計算書（TTM） | |
|---|---|
| 収益 | US$70.41m |
| 売上原価 | US$233.26m |
| 売上総利益 | -US$162.85m |
| その他の費用 | US$138.34m |
| 収益 | -US$301.19m |
直近の収益報告
Jun 30, 2025
次回決算日
該当なし
| 一株当たり利益（EPS） | -4.81 |
| グロス・マージン | -231.29% |
| 純利益率 | -427.77% |
| 有利子負債／自己資本比率 | 0% |
SAGE の長期的なパフォーマンスは？
過去の実績と比較を見る企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2025/08/01 07:49 |
| 終値 | 2025/07/30 00:00 |
| 収益 | 2025/06/30 |
| 年間収益 | 2024/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
Sage Therapeutics, Inc. 14 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。9
| アナリスト | 機関 |
|---|---|
| Esther Lannie Hong | Berenberg |
| null null | BMO Capital Markets Equity Research |
| Gary Nachman | BMO Capital Markets Equity Research |